DW71177

DW71177 is a novel [1,2,4]triazolo[4,3-a] quinoxaline-based potent and BD1-Selective BET inhibitor, and can be used for study of acute myeloid leukemia[1].

Product Specifications

CAS Number

[2241311-72-6]

UNSPSC

12352005

Target

Epigenetic Reader Domain

Type

Reference compound

Related Pathways

Epigenetics

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/dw71177.html

Purity

97.70

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CC1=NN=C2C(NCCCCNC(CC(C)C)=O)=NC3=CC(OC)=CC=C3N21

Molecular Formula

C20H28N6O2

Molecular Weight

384.48

References & Citations

[1]Ali I, et al. DW71177: A novel [1,2,4]triazolo[4,3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia. Eur J Med Chem. Published online December 16, 2023.